Efficacy of leukemia inhibitory factor in experimental autoimmune neuritis

J Neuroimmunol. 2002 Dec;133(1-2):56-9. doi: 10.1016/s0165-5728(02)00359-4.

Abstract

Leukemia inhibitory factor (LIF) is a pleiotropic cytokine that exerts neurotrophic and myotrophic actions. We have investigated the effect of LIF in experimental autoimmune neuritis (EAN), an animal model of Guillain-Barré syndrome (GBS). Treatment with LIF at the onset of the disease showed a slight, but not significant, improvement in the clinical course but no effect on nerve histology.

MeSH terms

  • Animals
  • Axons / drug effects
  • Axons / immunology
  • Axons / pathology
  • Body Weight / drug effects
  • Body Weight / immunology
  • Cauda Equina / drug effects
  • Cauda Equina / immunology
  • Cauda Equina / pathology
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Growth Inhibitors / pharmacology*
  • Growth Inhibitors / therapeutic use
  • Guillain-Barre Syndrome / drug therapy*
  • Interleukin-6*
  • Leukemia Inhibitory Factor
  • Lymphokines / pharmacology*
  • Lymphokines / therapeutic use
  • Myelin Sheath / drug effects
  • Myelin Sheath / immunology
  • Myelin Sheath / pathology
  • Neuritis, Autoimmune, Experimental / drug therapy*
  • Neuritis, Autoimmune, Experimental / pathology
  • Neuritis, Autoimmune, Experimental / physiopathology
  • Rats
  • Sciatic Nerve / drug effects
  • Sciatic Nerve / immunology
  • Sciatic Nerve / pathology
  • Spinal Nerve Roots / drug effects*
  • Spinal Nerve Roots / immunology
  • Spinal Nerve Roots / pathology
  • Treatment Outcome
  • Wallerian Degeneration / drug therapy
  • Wallerian Degeneration / immunology
  • Wallerian Degeneration / pathology

Substances

  • Growth Inhibitors
  • Interleukin-6
  • Leukemia Inhibitory Factor
  • Lymphokines